Phosphodiesterase type 5 inhibitors enhance chemotherapy in preclinical models of esophageal adenocarcinoma by targeting cancer-associated fibroblasts

Benjamin P. Sharpe(University of Southampton), Tim Underwood(Southampton General Hospital)
Cell Reports Medicine
June 1, 2022
10.1016/j.xcrm.2022.100541
Cited by 24

Related Papers

Cancer‐associated fibroblasts predict poor outcome and promote periostin‐dependent invasion in oesophageal adenocarcinoma
|The Journal of Pathology|2014|182
Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial
|˜The œLancet. Gastroenterology & hepatology|2019|64
Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma
|Gut|2019|27
Patient-derived tumor organoid and fibroblast assembloid models for interrogation of the tumor microenvironment in esophageal adenocarcinoma
|Cell Reports Methods|2024|10
Modulation of the tumour promoting functions of cancer associated fibroblasts by phosphodiesterase type 5 inhibition increases the efficacy of chemotherapy in human preclinical models of esophageal adenocarcinoma
|bioRxiv (Cold Spring Harbor Laboratory)|2020|2